Jpmorgan Chase & CO Rain Therapeutics Inc. Transaction History

Jpmorgan Chase & CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$0.84 - $1.22 $4,832 - $7,018	5,753 Added 50.17%	17,220 $20,000
Q3 2023 Nov 14, 2023	SELL	$0.82 - $1.42 $2,072 - $3,589	-2,528 Reduced 18.06%	11,467 $9,000
Q2 2023 Aug 11, 2023	BUY	$1.09 - $9.93 $14,761 - $134,481	13,543 Added 2996.24%	13,995 $16,000
Q4 2022 Feb 13, 2023	SELL	$5.52 - $8.48 $1,297 - $1,992	-235 Reduced 34.21%	452 $4,000
Q2 2022 Aug 11, 2022	SELL	$2.21 - $5.56 $19,730 - $49,639	-8,928 Reduced 92.85%	687 $4,000
Q1 2022 May 11, 2022	SELL	$5.07 - $13.68 $23,458 - $63,297	-4,627 Reduced 32.49%	9,615 $49,000
Q4 2021 Feb 10, 2022	BUY	$11.91 - $17.0 $135,690 - $193,681	11,393 Added 399.89%	14,242 $183,000
Q3 2021 Nov 12, 2021	BUY	$13.21 - $20.91 $37,635 - $59,572	2,849 New	2,849 $43,000

122K

Ticker RAIN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,837,400
Description
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.